跳至主要内容
临床试验/NCT01016028
NCT01016028撤回不适用

Chemotherapy-Induced Peripheral Neuropathy: Feasibility and Validity of New Symptom Measurement Tools in Patients on Treatment With Platinum Agents, Taxanes and Bortezomib

M.D. Anderson Cancer Center0 个研究点开始时间: 2009年11月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
主要终点
Assessment of Patient's Symptoms (Questionnaire)

研究概览

简要总结

The goal of this research study is to learn more about pain and other symptoms that patients may experience while receiving chemotherapy treatment with platinum agents, taxanes, and/or bortezomib.

详细描述

If patient agrees to take part in this study, they will be asked to complete 3 questionnaires, 3 sensory tests, and may be asked to take part in a one-on-one symptom interview.

Symptom Interview:

Depending on when patient is enrolled in this study, they may take part in a one-on-one interview with a study staff member. A total of 15 participants will take part in this interview (5 taking platinum agents, 5 taking taxanes, & 5 taking bortezomib). During the interview, patient will be asked to describe their symptoms. The interview should take about 20-30 minutes to complete.

The interviews will be digitally recorded, transcribed (typed), and used by researchers to identify symptoms related to receiving this type of chemotherapy. Researchers will use this information to design a study questionnaire that focuses on chemotherapy symptoms in the hands and feet. The digital recordings and typed copies of the interview will be destroyed after researchers have analyzed the interview data and the study is complete.

Questionnaires & Sensory Tests:

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients >= 18 years old.
  • Patients must be fluent with the English language.
  • Patients must be on chemotherapy regimes with any of the study drugs: cisplatin, oxaliplatin, taxanes and/or bortezomib.

排除标准

  • Significant cognitive impairment as determined by the trained research staff
  • Chronic alcoholism or substance abuse
  • Diagnosis of severe depression

结局指标

主要结局

Assessment of Patient's Symptoms (Questionnaire)

时间窗: Each patient administered questionnaire at single point in time.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验

进行中(未招募)
不适用
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Lung Non-Small Cell CarcinomaPrognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIB Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Stage I Lung Cancer AJCC v8Stage I Ovarian Cancer AJCC v8Stage IA Ovarian Cancer AJCC v8Stage IA1 Lung Cancer AJCC v8Stage IA2 Lung Cancer AJCC v8Stage IA3 Lung Cancer AJCC v8Stage IB Lung Cancer AJCC v8Stage IB Ovarian Cancer AJCC v8Stage IC Ovarian Cancer AJCC v8Stage II Lung Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage IIA Lung Cancer AJCC v8Stage IIA Ovarian Cancer AJCC v8Stage IIB Lung Cancer AJCC v8Stage IIB Ovarian Cancer AJCC v8Stage III Lung Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8Stage IIIA1 Ovarian Cancer AJCC v8Stage IIIA2 Ovarian Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIB Ovarian Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8
NCT03939481SWOG Cancer Research Network1,336
招募中
4 期
Preventive Approach Using VenlafaxinePeripheral Neuropathy Due to Chemotherapy
NCT05875610Mit Ghamr Oncology Center60
Unknown
不适用
A Feasibility Study Investigating Chemotherapy-induced Neuropathy Using Multi-frequency Tactilometry and Patient-reported Outcomes (PRO)Chemotherapy-induced Peripheral Neuropathy
NCT04167319Zealand University Hospital32
已完成
2 期
MC-5A for Chemotherapy Induced Peripheral NeuropathyNeuropathy, Paraneoplastic
NCT01261780University of Wisconsin, Madison14
尚未招募
不适用
CIPN and it's Impact on Quality of Life in Patients Receiving Platinum and TaxanesChemotherapy-induced Peripheral Neuropathy
NCT05829967Assiut University60